会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明授权
    • Voice activity decision base on zero crossing rate and spectral sub-band energy
    • 基于零交叉率和频谱子带能量的语音活动决策
    • US08296133B2
    • 2012-10-23
    • US13307683
    • 2011-11-30
    • Zhe Wang
    • Zhe Wang
    • G10L11/06G10L21/02G10L15/20G10L17/00
    • G10L25/78G10L25/09
    • A voice activity detection method and apparatus, and an electronic device are provided. The method includes: obtaining a time domain parameter and a frequency domain parameter from an audio frame; obtaining a first distance between the time domain parameter and a long-term sliding mean of the time domain parameter in a history background noise frame, and obtaining a second distance between the frequency domain parameter and a long-term sliding mean of the frequency domain parameter in the history background noise frame; and judging whether the audio frame is a foreground voice frame or a background noise frame according to the first distance, the second distance and a set of decision inequalities based on the first distance and the second distance. The above technical solutions enable the judgment criterion to have an adaptive adjustment capability, thus improving the performance of the voice activity detection.
    • 提供语音活动检测方法和装置以及电子装置。 该方法包括:从音频帧获得时域参数和频域参数; 在历史背景噪声帧中获得时域参数与时域参数的长期滑动均值之间的第一距离,并获得频域参数与频域参数的长期滑动平均值之间的第二距离 在历史背景噪音框架; 以及根据所述第一距离,所述第二距离和基于所述第一距离和所述第二距离的一组判定不等式来判断所述音频帧是前景语音帧还是背景噪声帧。 上述技术方案使得判断标准具有自适应调整能力,从而提高语音活动检测的性能。
    • 13. 发明授权
    • Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
    • 桥联碳环肟丙型肝炎病毒丝氨酸蛋白酶抑制剂
    • US08283309B2
    • 2012-10-09
    • US12338612
    • 2008-12-18
    • Dong LiuYat Sun OrZhe Wang
    • Dong LiuYat Sun OrZhe Wang
    • A61K38/00
    • C07D273/00
    • The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. More specifically, the invention relates to oxime compounds containing a carbocyclic P2 unit, and the oxime is tethered to one of the carboxylic acid on P2. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    • 本发明公开了式I化合物或其药学上可接受的盐,酯或前药:其抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒(HCV)NS3-NS4A蛋白酶的活性。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 更具体地,本发明涉及含有碳环P2单元的肟化合物,并且肟与P2上的一种羧酸结合。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
    • 15. 发明授权
    • C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
    • C5取代的,脯氨酸衍生的大环丙型肝炎丝氨酸蛋白酶抑制剂
    • US08263549B2
    • 2012-09-11
    • US12324071
    • 2008-11-26
    • Joel D. MooreYat Sun OrZhe Wang
    • Joel D. MooreYat Sun OrZhe Wang
    • A61K38/00
    • C07K5/06165A61K38/00C07K5/0812
    • The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    • 本发明涉及式I化合物或其药学上可接受的盐,酯或前药:其抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒(HCV)NS3-NS4A蛋白酶的活性。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
    • 19. 发明授权
    • Method and device for tracking background noise in communication system
    • 用于跟踪通信系统背景噪声的方法和装置
    • US08095361B2
    • 2012-01-10
    • US13116323
    • 2011-05-26
    • Zhe Wang
    • Zhe Wang
    • G10L21/02G10L15/20
    • G10L21/0208G10L25/84
    • A method and a device for tracking background noise in a communication system, where the method includes: calculating a SNR of a current frame according to input audio signals; increasing a frame counter, and calculating tone features and signal steadiness features of the current frame if the SNR of the current frame is not smaller than a first threshold; judging the possibility of a time window including a noise interval according to the calculated tone feature values and signal steadiness feature values of each frame of the time window when the frame counter is increased to the length of the time window; and extracting noise features in the time window. Existence of background noise is analyzed continuously in a time window, so that background noise that changes frequently and dramatically can be detected or tracked rapidly.
    • 一种在通信系统中跟踪背景噪声的方法和装置,其中该方法包括:根据输入的音频信号计算当前帧的SNR; 增加帧计数器,并且如果当前帧的SNR不小于第一阈值,则计算当前帧的色调特征和信号稳定特征; 当帧计数器增加到时间窗口的长度时,根据所计算的色调特征值和时间窗口的每个帧的信号稳定特征值来判断包括噪声间隔的时间窗口的可能性; 并在时间窗口中提取噪声特征。 在时间窗口中连续分析背景噪声的存在,从而可以快速检测或跟踪快速变化的背景噪声。